Traditional Chinese Medicine for Inhibiting Ferroptosis in Ischemic‐Related Diseases
Basic & Clinical Pharmacology & Toxicology · 2025
DOI: 10.1111/bcpt.70039 ↗At a glance
Übersichtsarbeit in Basic & Clinical Pharmacology & Toxicology, 2025. Written by Yukun Zhang and 3 co-authors. Institution: Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing, China. Major MEDLINE topics: Ferroptosis, Medicine, Chinese Traditional, Drugs, Chinese Herbal, Ischemia. Cited 1 times so far (Crossref); 121 references. Funded by: National Natural Science Foundation of China, Science and Technology Research Project of Chongqing Education Commission, Wanzhou District Social Welfare Research Project.
Abstract (original language)
Ischemic‐related diseases, such as myocardial infarction and stroke, are primarily driven by a deficit in oxygen supply leading to cellular damage and death. Ferroptosis has emerged as an important mechanism contributing to the progression of ischemic injury, characterized by iron‐dependent lipid peroxidation. This review aims to provide a comprehensive overview of the significant mechanisms underlying ferroptosis in ischemic conditions and explores the potential effects of traditional Chinese medicines (TCMs) and their extracts. Numerous compounds extracted from TCMs, including flavonoids, polyphenols and terpenes, exhibit potent antiferroptotic effects by activating nuclear factor erythroid 2–related factor 2, upregulating glutathione peroxidase 4, inhibiting lipid peroxidation and so on. These properties render TCMs a promising candidate for developing novel ferroptosis therapeutic strategies. This review underscores the importance of investigating the interactions between ferroptosis and TCMs within the context of ischemic diseases. These findings provide valuable insights for future research to identify targets associated with ferroptosis regulation, thereby expanding the pharmacological perspective of TCMs in treating ischemic diseases and revealing the potential of novel therapeutic strategies. Additionally, this highlights the relevance of integrating traditional and modern medical approaches in addressing complex health issues.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area, Chongqing, China.
- State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, China.
ORCID profiles: Yukun Zhang
Funding
- National Natural Science Foundation of China
- Science and Technology Research Project of Chongqing Education Commission
- Wanzhou District Social Welfare Research Project
- Proof of Concept Project of Medical Innovation Center (Taizhou) of Peking University
- Key Laboratory Special Project of Chongqing Three Gorges Medical College
Cite
APA
Zhang, Y., Yao, Y., Zhang, Q., & Yang, B. (2025). Traditional Chinese Medicine for Inhibiting Ferroptosis in Ischemic‐Related Diseases. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70039
Vancouver
Zhang Y, Yao Y, Zhang Q, Yang B. Traditional Chinese Medicine for Inhibiting Ferroptosis in Ischemic‐Related Diseases. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70039
BibTeX
@article{Zhang2025,
author = {Zhang, Yukun and Yao, Yang and Zhang, Qiaoling and Yang, Baoxue},
title = {Traditional Chinese Medicine for Inhibiting Ferroptosis in Ischemic‐Related Diseases},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
doi = {10.1111/bcpt.70039}
}
EUVIMED